by adminmps | Apr 29, 2022 | News, Resources
The Canadian MPS Society has been strongly advocating to add MPS I-H (Hurler Syndrome) to all newborn screening panels throughout Canada. To date, MPS I-H has been added to the Ontario Newborn Screening Panel, with the strong advocacy efforts of Newborn Screening...
by adminmps | Apr 29, 2022 | Uncategorized
MPS I Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH). Read the full report >> SiglionTherapeutics, Development of a Novel...
by adminmps | Apr 29, 2022 | News, Resources
Ultragenyx has relaunched their patient support interactive website, UltraRareAdvocacy.com with a refreshed design and more ways to connect with rare disease communities. Visitors will find: More rare experiences from individuals and families living with...
by adminmps | Apr 29, 2022 | Clinical Trials, News, Research, Treatment
We are excited to hear that Elosulfase alfa – branded as Vimizin and made by BioMarin – has been recommended by NICE (National Institute for Health and Care Excellence) for treating MPS IVA Morquio in England and Wales. Newly diagnosed patients and...
by adminmps | Apr 29, 2022 | Clinical Trials, News, Research
Mathias Schmidt, PhD, President and CEO of JCR Pharmaceuticals USA, discusses long-term efficacy and safety data of pabinafusp-alfa (Izcargo) in mucopolysaccharidosis type II (MPS II; Hunter syndrome). (Data from this study was recently presented...
